X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2383) 2383
animals (1486) 1486
humans (1260) 1260
male (802) 802
biochemistry & molecular biology (734) 734
epoprostenol - pharmacology (681) 681
epoprostenol - biosynthesis (659) 659
rats (635) 635
prostacyclin (620) 620
epoprostenol - metabolism (527) 527
cells, cultured (485) 485
female (472) 472
in vitro techniques (347) 347
pharmacology & pharmacy (339) 339
epoprostenol - analogs & derivatives (279) 279
cell biology (265) 265
endothelium, vascular - metabolism (262) 262
platelet aggregation - drug effects (242) 242
mice (227) 227
endocrinology & metabolism (220) 220
kinetics (216) 216
endothelium, vascular - drug effects (215) 215
dose-response relationship, drug (214) 214
adult (197) 197
blood platelets - metabolism (193) 193
arachidonic acid (190) 190
abridged index medicus (188) 188
prostaglandins (182) 182
rabbits (181) 181
cattle (176) 176
cyclic amp - metabolism (165) 165
receptors, epoprostenol (165) 165
blood platelets - drug effects (163) 163
endothelium (160) 160
time factors (159) 159
arachidonic acids - metabolism (147) 147
endothelium, vascular - cytology (142) 142
middle aged (137) 137
rats, inbred strains (131) 131
epoprostenol - blood (128) 128
calcium - metabolism (124) 124
expression (124) 124
aorta - metabolism (123) 123
prostaglandins - biosynthesis (122) 122
rats, sprague-dawley (122) 122
iloprost (121) 121
indomethacin - pharmacology (120) 120
epoprostenol - physiology (117) 117
muscle, smooth, vascular - drug effects (117) 117
prostaglandins - pharmacology (115) 115
receptors, prostaglandin - metabolism (115) 115
platelets (114) 114
dogs (112) 112
cell line (111) 111
nitric oxide (110) 110
rats, wistar (110) 110
epoprostenol - therapeutic use (109) 109
cells (107) 107
pregnancy (107) 107
nitric oxide - metabolism (106) 106
prostaglandin-endoperoxide synthases - metabolism (106) 106
muscle, smooth, vascular - metabolism (105) 105
platelet aggregation (104) 104
signal transduction (104) 104
thrombin - pharmacology (104) 104
6-ketoprostaglandin f1 alpha - metabolism (98) 98
prostaglandins - metabolism (97) 97
biophysics (96) 96
nitric-oxide (94) 94
chemistry (93) 93
hematology (92) 92
blood pressure - drug effects (90) 90
iloprost - pharmacology (90) 90
endothelium - metabolism (88) 88
phosphorylation (88) 88
aspirin - pharmacology (86) 86
enzyme inhibitors - pharmacology (86) 86
peripheral vascular disease (86) 86
inhibition (84) 84
platelet aggregation inhibitors - pharmacology (84) 84
thromboxane a2 - biosynthesis (84) 84
swine (81) 81
endothelial-cells (80) 80
6-ketoprostaglandin f1 alpha - biosynthesis (79) 79
activation (79) 79
arachidonic-acid (79) 79
epoprostenol (79) 79
calcimycin - pharmacology (78) 78
hypertension, pulmonary - drug therapy (78) 78
chemistry, medicinal (77) 77
lipids (76) 76
physiology (76) 76
hypertension (74) 74
dinoprostone - biosynthesis (72) 72
k cq biochemistry & molecular biology (72) 72
thromboxane (72) 72
endothelial cells (71) 71
chemical phenomena (70) 70
receptor (70) 70
bradykinin - pharmacology (69) 69
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2389) 2389
Chinese (15) 15
Russian (9) 9
Japanese (7) 7
German (3) 3
French (2) 2
Hungarian (2) 2
Danish (1) 1
Dutch (1) 1
Polish (1) 1
Portuguese (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of Controlled Release, ISSN 0168-3659, 01/2015, Volume 197, pp. 97 - 104
Prostaglandin I (PGI ) and its analogues (such as beraprost sodium, BPS) are beneficial for the treatment of pulmonary arterial hypertension (PAH). The... 
Encapsulation | Biodegradable nanoparticle | Pulmonary arterial hypertension | Prostaglandin I2 | Beraprost sodium | Prostaglandin I | SURVIVAL | RATS | VASCULAR-PERMEABILITY | CONTINUOUS INTRAVENOUS EPOPROSTENOL | BIODEGRADABLE NANOPARTICLES | COMBINATION | CHEMISTRY, MULTIDISCIPLINARY | THERAPY | Prostaglandin I-2 | PROSTACYCLIN ANALOG | NANOSPHERES | PHARMACOLOGY & PHARMACY | REGISTRY | Polymers - administration & dosage | Rhodamines - administration & dosage | Nanoparticles - chemistry | Rats, Wistar | Monocrotaline | Capillary Permeability - drug effects | Drug Carriers - administration & dosage | Delayed-Action Preparations - chemistry | Male | Polyethylene Glycols - chemistry | Drug Carriers - chemistry | Delayed-Action Preparations - administration & dosage | Pulmonary Artery - metabolism | Delayed-Action Preparations - pharmacokinetics | Polyesters | Hypertension, Pulmonary - drug therapy | Rhodamines - chemistry | Lactic Acid - administration & dosage | Disease Models, Animal | Epoprostenol - pharmacokinetics | Lactic Acid - chemistry | Mice, Inbred C57BL | Hypertension, Pulmonary - metabolism | Pulmonary Artery - drug effects | Polyethylene Glycols - administration & dosage | Epoprostenol - analogs & derivatives | Animals | Epoprostenol - chemistry | Polymers - chemistry | Drug Carriers - pharmacokinetics | Nanoparticles - administration & dosage | Hypertension, Pulmonary - pathology | Pulmonary Artery - pathology | Epoprostenol - administration & dosage | Nanoparticles | Fluorescence | Models | Analysis | Pulmonary hypertension | Drugs | Drug delivery systems | Drug discovery | Vehicles | Index Medicus
Journal Article
Journal Article
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 06/2013, Volume 56, Issue 11, pp. 4277 - 4299
3-(5-Chlorofuran-2-yl)-5-methyl-4-phenylisoxazole (P6), a known selective cyclooxygenase-1 (COX-1) inhibitor, was used to design a new series of... 
CROSS-TALK | CHEMISTRY, MEDICINAL | LOW-DOSE ASPIRIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | HEALTHY-SUBJECTS | STRUCTURAL BASIS | ACTIVE-SITE | VESSEL WALL INTERACTIONS | THROMBOXANE BIOSYNTHESIS | PROSTANOID FORMATION | ARACHIDONIC-ACID | Fibrinolytic Agents - chemistry | Epoprostenol - metabolism | Furans - pharmacology | Humans | Structure-Activity Relationship | Cyclooxygenase 2 Inhibitors - chemistry | Isoxazoles - chemical synthesis | Platelet Aggregation Inhibitors - chemical synthesis | Furans - chemistry | Platelet Aggregation Inhibitors - pharmacology | Thromboxane A2 - antagonists & inhibitors | Female | Fibrinolytic Agents - chemical synthesis | Platelet Aggregation - drug effects | Blood Platelets - drug effects | Thromboxane A2 - biosynthesis | Cyclooxygenase 2 Inhibitors - chemical synthesis | Cell Line | Cyclooxygenase 2 Inhibitors - pharmacology | Mice, Inbred C57BL | Cyclooxygenase Inhibitors - chemistry | Isoxazoles - chemistry | Cyclooxygenase Inhibitors - pharmacology | Isoxazoles - pharmacology | Fibrinolytic Agents - pharmacology | Animals | Blood Platelets - metabolism | Cyclooxygenase 2 - metabolism | Cyclooxygenase Inhibitors - chemical synthesis | Platelet Aggregation Inhibitors - chemistry | Platelet-Rich Plasma | Mice | Molecular Docking Simulation | Cyclooxygenase 1 - metabolism | Furans - chemical synthesis | Index Medicus
Journal Article
Biochemistry, ISSN 0006-2960, 06/2015, Volume 54, Issue 23, pp. 3707 - 3715
In vascular inflammation, prostaglandin E2 (PGE(2)) is largely biosynthesized by microsomal PGE2 synthase-1 (mPGES-1), competing with other downstream... 
PROSTAGLANDIN-E SYNTHASE | PROSTATE | PROSTACYCLIN | BIOCHEMISTRY & MOLECULAR BIOLOGY | ENDOTHELIAL-CELLS | ARACHIDONIC-ACID | E-2 | CYCLOOXYGENASE | Arachidonic Acid - metabolism | Epoprostenol - metabolism | Molecular Weight | Humans | Peptides - genetics | Cytochrome P-450 Enzyme System - metabolism | Recombinant Fusion Proteins - metabolism | Peptides - metabolism | Cyclooxygenase 2 - genetics | HEK293 Cells | Protein Engineering | Cyclooxygenase 1 - chemistry | Intramolecular Oxidoreductases - metabolism | Endoplasmic Reticulum, Smooth - enzymology | Oligopeptides - chemistry | Peptide Fragments - genetics | Cyclooxygenase 1 - genetics | Peptide Fragments - metabolism | Prostaglandin H2 - metabolism | Intramolecular Oxidoreductases - chemistry | Peptides - chemistry | Protein Structure, Secondary | Cyclooxygenase 2 - chemistry | Oligopeptides - genetics | Oligopeptides - metabolism | Recombinant Fusion Proteins - chemistry | Protein Transport | Dinoprostone - metabolism | Cytochrome P-450 Enzyme System - chemistry | Peptide Fragments - chemistry | Intramolecular Oxidoreductases - genetics | Endoplasmic Reticulum, Smooth - metabolism | Models, Biological | Prostaglandin-E Synthases | Cyclooxygenase 2 - metabolism | Cytochrome P-450 Enzyme System - genetics | Cyclooxygenase 1 - metabolism | Inflammation | Research | Topology | Algebraic topology | Endoplasmic reticulum | Index Medicus
Journal Article
Journal Article
Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 12/2017, Volume 363, Issue 3, pp. 348 - 357
This article describes the preclinical pharmacology and pharmacokinetics (PK) of hexadecyl-treprostinil (C16TR), a prodrug of treprostinil (TRE), formulated in... 
PROSTACYCLIN RECEPTOR | EP4 RECEPTOR | ANALOGS | ARTERIAL-HYPERTENSION | PHARMACOLOGY & PHARMACY | BINDING | ILOPROST | Antihypertensive Agents - pharmacology | Nanoparticles - chemistry | Vasodilator Agents - pharmacokinetics | Phosphatidylethanolamines - adverse effects | Humans | Excipients - adverse effects | Male | Polyethylene Glycols - chemistry | Squalene - analogs & derivatives | Drug Compounding | Hypertension, Pulmonary - drug therapy | Epoprostenol - pharmacokinetics | Guinea Pigs | Squalene - adverse effects | Antihypertensive Agents - therapeutic use | Excipients - administration & dosage | Rats, Sprague-Dawley | Epoprostenol - analogs & derivatives | Lung - drug effects | Vasodilation - drug effects | Phosphatidylethanolamines - chemistry | Drug Delivery Systems - adverse effects | Epoprostenol - administration & dosage | Prodrugs - administration & dosage | Epoprostenol - metabolism | Vasodilator Agents - therapeutic use | Antihypertensive Agents - administration & dosage | Polyethylene Glycols - adverse effects | Hypertension, Pulmonary - blood | Nanoparticles - adverse effects | Dose-Response Relationship, Drug | Epoprostenol - therapeutic use | Excipients - chemistry | Epoprostenol - pharmacology | Female | Lung - metabolism | Platelet Aggregation - drug effects | Drug Evaluation, Preclinical | Squalene - chemistry | Vasodilator Agents - pharmacology | Administration, Inhalation | Phosphatidylethanolamines - administration & dosage | Squalene - administration & dosage | Antihypertensive Agents - pharmacokinetics | Polyethylene Glycols - administration & dosage | Animals | Prodrugs - pharmacokinetics | Dogs | Nanoparticles - administration & dosage | Prodrugs - therapeutic use | Lung - blood supply | Prodrugs - pharmacology | Vasodilator Agents - administration & dosage | Index Medicus
Journal Article
Journal Article
Nature chemical biology, 01/2019, Volume 15, Issue 1, p. 18
Journal Article
Journal Article
Journal Article